Pharmaceutical executives are losing control of their product narratives. While marketing teams focus on search engine optimization and field sales, […]
Stop AI Hallucinations From Destroying Your Drug Brand Value Read Post »
Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own
Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat
A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of
The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is
The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market
Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents Read Post »
What FTO Actually Means (And What It Doesn’t) The Legal Definition and Its Limits Freedom-to-operate analysis is one of the
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma Read Post »
Get fresh news and insights, drug patent expirations & more…
